Biogen opened higher at $255.39, compared with its previous close of $249.65. In the last trading session, the stock traded between $252.23 and $258.73. It showed an upward intraday trend.
An investment of $100 made 5 years ago in Biogen is now worth
$ 95.13
resulting in a loss of
$ 4.87 (4.87%)
Note: Past profits do not guarantee future returns.
Rating from 24 Analysts
Today's Change
+$4.04 (+1.62%)
Day High
$258.73
Day Low
$252.23
Day Open
$255.39
Prev Close
$249.65
Volume
5,82,553
1W Return
-0.03%
1M Return
11.71%
3M Return
21.18%
6M Return
30.51%
1Y Return
71.58%
Market Cap ($ Mn)
37,501
PE Ratio
38.81
PB Ratio
1.71
PEG Ratio
31.98
ROE
7.36%
ROCE
6.94%
EPS (TTM)
$-0.14
1 Week
-0.03%
1 Month
11.71%
3 Months
21.18%
6 Months
30.51%
9 Months
44.00%
TD Cowen maintains buy on Biogen, lifts price target to $250
TD Cowen maintains a Buy rating on Biogen. Price target raised from $225 to $250. Analyst Phil Nadeau issued the updated recommendation.
9 days agoWells Fargo maintains overweight on Biogen, raises price target to $310
Wells Fargo analyst Mohit Bansal maintains Overweight rating on Biogen. Price target raised from $250 to $310. New target implies a $60 increase from previous valuation.
10 days agoBiogen to present 76-week EMPAVELI data at ASN Kidney Week
Biogen presents 76-week EMPAVELI data showing sustained proteinuria reduction and eGFR stabilization. FDA recently expanded EMPAVELI indication to include reducing loss of kidney function in C3G and IC-MPGN. Felzartamab, an investigational anti-CD38 antibody, is under study in three Phase 3 trials for various kidney diseases. TRANSCEND study data for antibody-mediated rejection is expected in the first half of 2027.
11 days agoBiogen litifilimab shows durable efficacy in 52-week lupus trial
Litifilimab showed continued improvement in skin disease activity through Week 52 in the AMETHYST Phase 2 study. 27.2% of patients achieved clear or almost clear skin by Week 52, up from 19.0% at Week 24. Participants switching from placebo to litifilimab saw rapid benefit within four weeks. The drug maintained a consistent safety profile with no new safety signals identified over 52 weeks.
28 days agoBiogen EMPAVELI cuts proteinuria 75% in adolescents with rare kidney disease
Biogen published Phase 3 VALIANT adolescent subgroup data in CJASN on Sept. 17, 2026. EMPAVELI achieved 75% relative proteinuria reduction vs placebo in teens aged 12-17. 71% of treated adolescents saw ≥50% proteinuria drop, compared to 4% on placebo. Drug remains the only approved therapy for C3G and primary IC-MPGN in patients 12+. Findings support recent FDA label expansion for kidney function preservation.
1mo agoBiogen completes RayThera acquisition to expand immunology pipeline
Biogen Inc. finalized the acquisition of RayThera Inc. on Aug. 06, 2026, adding small-molecule immunology therapies to its pipeline. The lead asset entered Phase 1 trials in July 2026, supporting Biogen’s open innovation strategy. Executive Priya Singhal cited the deal as key to long-term portfolio diversification.
2mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $1,373.70 | +6.63% | $12,93,142.11M | 39.43 | |
| $275.20 | +1.53% | $6,62,491.71M | 31.06 | |
| $290.79 | +1.68% | $5,13,859.95M | 72.17 | |
| $146.33 | +3.83% | $3,61,021.28M | 117.74 | |
| $161.10 | +3.22% | $3,27,809.50M | 23.23 | |
| $174.40 | +2.88% | $2,70,478.36M | 24.32 | |
| $460.73 | +1.97% | $2,49,085.38M | 26.86 | |
| $165.61 | +4.03% | $2,05,348.95M | - | |
| $29.95 | +1.70% | $1,70,705.24M | 36.79 | |
| $39.14 | +2.22% | $1,32,689.61M | 11.15 | |
| $61.39 | +1.35% | $1,25,402.27M | 14.67 | |
| $48.68 | -0.12% | $1,05,059.03M | 16.01 |
An investment of $100 made 5 years ago in Biogen is now worth
$ 95.13
resulting in a loss of
$ 4.87 (4.87%)
Note: Past profits do not guarantee future returns.
